Photoimmunotherapy for Managing Recurrent Laryngeal Cancer Cervical Lesions: A Case Report

Photoimmunotherapy (PIT) targets and destroys tumor cells through irradiation with 690-nm red light after the administration of cetuximab sarotalocan sodium, which contains IRDye700DX bound to cetuximab. In Japan, PIT is a new treatment that is covered by insurance only for unresectable head and nec...

Descripción completa

Detalles Bibliográficos
Autores principales: Okamoto, Isaku, Okada, Takuro, Tokashiki, Kunihiko, Tsukahara, Kiyoaki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: S. Karger AG 2022
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8832182/
https://www.ncbi.nlm.nih.gov/pubmed/35221967
http://dx.doi.org/10.1159/000521435

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8832182/
https://www.ncbi.nlm.nih.gov/pubmed/35221967
http://dx.doi.org/10.1159/000521435

Ejemplares similares